Viridian Therapeutics(VRDN)
$30.48-0.77 (-2.46%)
VRDN
Viridian Therapeutics financials statements
$30.48
At close:-0.77 (-2.46%)
Want to see VRDN full AI Analyst Report?
Viridian Therapeutics (VRDN) Ratios
1,572 Followers
Viridian Therapeutics Ratios
VRDN's free cash flow for Q3 2026 was $-93.14M. For the 2026 fiscal year, VRDN's free cash flow was decreased by $-370.00K and operating cash flow was $-92.77M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 12.65 | 15.43 | 18.26 | 12.73 | 14.68 |
| Quick Ratio | 12.65 | 15.43 | 18.26 | 12.93 | 14.68 |
| Cash Ratio | 3.00 | 2.08 | 3.86 | 4.67 | 3.10 |
| Solvency Ratio | -1.93 | -3.80 | -4.90 | -3.24 | -4.96 |
| Operating Cash Flow Ratio | -3.91 | -4.85 | -6.91 | -2.81 | -4.00 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 716.98M | $ 667.70M | $ 438.08M | $ 384.52M | $ 184.17M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.06 | 0.03 | 0.04 | 0.01 | 0.00 |
| Debt-to-Equity Ratio | 0.07 | 0.03 | 0.05 | 0.01 | 0.00 |
| Debt-to-Capital Ratio | 0.07 | 0.03 | 0.05 | 0.01 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.06 | 0.03 | 0.04 | 0.01 | 0.00 |
| Financial Leverage Ratio | 1.25 | 1.11 | 1.11 | 1.10 | 1.09 |
| Debt Service Coverage Ratio | -68.15 | -87.22 | -127.43 | -265.71 | -26430.00 |
| Interest Coverage Ratio | -73.44 | -98.17 | -137.76 | -276.35 | -26576.00 |
| Debt to Market Cap | 0.02 | 0.02 | 0.02 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.66 | 0.36 | 0.51 | 0.18 | 0.04 |
| Net Debt to EBITDA | 0.48 | 0.30 | 0.35 | 1.16 | 0.53 |
| Profitability Margins | |||||
| Gross Profit Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBIT Margin | -476.58% | -88378.48% | -75123.25% | -7301.81% | -2680.05% |
| EBITDA Margin | -475.93% | -87967.88% | -74957.01% | -7287.42% | -2676.00% |
| Operating Profit Margin | -512.91% | -99018.21% | -81035.03% | -7579.23% | -2690.79% |
| Pretax Profit Margin | -483.57% | -89387.09% | -75711.46% | -7329.23% | -2680.16% |
| Net Profit Margin | -483.57% | -89387.09% | -75711.46% | -7329.23% | -2680.16% |
| Continuous Operations Profit Margin | -483.57% | -89387.09% | -75711.46% | -7329.23% | -2680.16% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 94.28% | 90.27% | 93.43% | 96.70% | 99.60% |
| Return on Assets (ROA) | -38.09% | -36.36% | -48.48% | -29.85% | -38.98% |
| Return on Equity (ROE) | -47.44% | -40.19% | -53.78% | -32.87% | -42.30% |
| Return on Capital Employed (ROCE) | -43.85% | -43.06% | -54.86% | -33.43% | -41.95% |
| Return on Invested Capital (ROIC) | -43.81% | -43.02% | -54.76% | -33.38% | -41.83% |
| Return on Tangible Assets | -38.09% | -36.36% | -48.48% | -29.85% | -38.98% |
| Earnings Yield | -12.98% | -20.74% | -24.39% | -13.86% | -33.70% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 3.08 | 17.37 | 6.57 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 19.42 | 0.09 | 0.09 | 0.60 | 1.44 |
| Asset Turnover | 0.08 | 0.00 | 0.00 | 0.00 | 0.01 |
| Working Capital Turnover Ratio | 0.09 | 0.00 | 0.00 | 0.01 | 0.02 |
| Cash Conversion Cycle | 0.00 | 0.00 | 118.57 | 21.01 | 55.56 |
| Days of Sales Outstanding | 0.00 | 0.00 | 118.57 | 21.01 | 55.56 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 118.57 | 21.01 | 55.56 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -3.26 | -3.42 | -4.12 | -2.92 | -4.58 |
| Free Cash Flow Per Share | -3.27 | -3.43 | -4.14 | -2.95 | -4.61 |
| Dividend Paid and CapEx Coverage Ratio | -558.37 | -454.64 | -205.09 | -117.74 | -161.48 |
| Capital Expenditure Coverage Ratio | -558.37 | -454.64 | -205.09 | -117.74 | -161.48 |
| Operating Cash Flow Coverage Ratio | -5.45 | -11.01 | -8.75 | -17.85 | -104.96 |
| Operating Cash Flow to Sales Ratio | -3.90 | -769.27 | -586.53 | -52.96 | -18.42 |
| Free Cash Flow Yield | -10.49% | -17.89% | -18.99% | -10.10% | -23.31% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -9.37 | -4.82 | -4.10 | -7.22 | -2.97 |
| Price-to-Sales (P/S) Ratio | 37.25 | 4309.19 | 3104.38 | 528.93 | 79.53 |
| Price-to-Book (P/B) Ratio | 3.65 | 1.94 | 2.21 | 2.37 | 1.26 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -9.53 | -5.59 | -5.27 | -9.90 | -4.29 |
| Price-to-Operating Cash Flow Ratio | -9.55 | -5.60 | -5.29 | -9.99 | -4.32 |
| Price-to-Earnings Growth (PEG) Ratio | 0.57 | 0.19 | -0.11 | 0.17 | 0.04 |
| Enterprise Value Multiple | -7.35 | -4.60 | -3.79 | -6.09 | -2.44 |
| Enterprise Value | 2.48B | 1.22B | 893.00M | 786.95M | 193.85M |
| EV to EBITDA | -7.35 | -4.60 | -3.79 | -6.09 | -2.44 |
| EV to Sales | 34.97 | 4049.26 | 2843.93 | 444.10 | 65.42 |
| EV to Free Cash Flow | -8.95 | -5.25 | -4.83 | -8.32 | -3.53 |
| EV to Operating Cash Flow | -8.96 | -5.26 | -4.85 | -8.39 | -3.55 |
| Tangible Book Value Per Share | 8.52 | 9.89 | 9.88 | 12.31 | 15.75 |
| Shareholders’ Equity Per Share | 8.52 | 9.89 | 9.88 | 12.31 | 15.75 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.84 | 0.00 | 0.01 | 0.06 | 0.25 |
| Net Income Per Share | -4.04 | -3.98 | -5.31 | -4.05 | -6.66 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.01 | 1.01 | 1.01 | 1.00 | 1.00 |
| Research & Development to Revenue | 4.78 | 788.92 | 508.81 | 56.94 | 19.20 |
| SG&A to Revenue | 1.35 | 202.26 | 302.54 | 19.85 | 8.71 |
| Stock-Based Compensation to Revenue | 0.63 | 139.57 | 213.92 | 11.15 | 4.88 |
| Income Quality | 0.81 | 0.86 | 0.77 | 0.72 | 0.69 |
Currency in USD
